Galera Therapeutics

FDA Decisions 2023: Sandoz, Gilead Sciences and More
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
Flag link:
Fierce Biotech Layoff Tracker 2023: Bayer-bought BlueRock makes cuts; Alaunos lets go 60% of teams
Fierce Biotech Layoff Tracker 2023: Bayer-bought BlueRock makes cuts; Alaunos lets go 60% of teams
Fierce Biotech
layoffs
Alaunos Therapeutics
BlueRock Therapeutics
Thermo Fisher
Bristol Myers Squibb
Atreca
Galera Therapeutics
Inovio
Salarius Pharmaceuticals
Karyopharm Therapeutics
Intergalatic Therapeutics
Flag link:
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates
Yahoo/Zacks.com
earnings
Legend Biotech
Kodiak Sciences
Galera Therapeutics
Flag link:
Galera Lays Off 70% of Staff After FDA Rejection in Severe Oral Mucositis
Galera Lays Off 70% of Staff After FDA Rejection in Severe Oral Mucositis
BioSpace
Galera Therapeutics
avasopasem manganese
layoffs
oral mucositis
head and neck cancer
FDA
Flag link:
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
BioSpace
FDA
graft vs host disease
head and neck cancer
postpartum depression
major depressive disorder
Mesoblast
remestemcel-L
Biogen
SAGE Therapeutics
zuranolone
Galera Therapeutics
avasopasem manganese
Flag link:
Galera earns key FDA designation for pancreatic cancer drug
Galera earns key FDA designation for pancreatic cancer drug
Clinical Trials Arena
Galera Therapeutics
pancreatic cancer
FDA
rucosopasem
orphan drugs
Flag link:
Galera's stock plunges 73% on disappointing test results for lead cancer drug candidate
Galera's stock plunges 73% on disappointing test results for lead cancer drug candidate
Bizjournals
Galera Therapeutics
cancer
clinical trials
head and neck cancer
oral mucositis
GC4419
Flag link:
Galera claims positive update in pancreatic cancer but doesn't report p-values
Galera claims positive update in pancreatic cancer but doesn't report p-values
Endpoints
Galera Therapeutics
pancreatic cancer
GC4419
Flag link:
Eyeing $86M, Galera leads a pack of three modest biotech IPOs pushing past high profile stumbles
Eyeing $86M, Galera leads a pack of three modest biotech IPOs pushing past high profile stumbles
Endpoints
IPOs
Galera Therapeutics
89Bio
Centogene
Flag link:
Clarus spearheads a big, $150M raise so Galera can flip the PhIII card on its new drug to treat radiation effects
Clarus spearheads a big, $150M raise so Galera can flip the PhIII card on its new drug to treat radiation effects
Endpoints
Galera Therapeutics
Flag link: